title: Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers.
abstract: To identify distinct antibody profiles among adults 50-to-74 years old using influenza A/H1N1 HI titers up to 75 days after vaccination. Healthy subjects 50 to 74 years old received the 2010-2011 trivalent inactivated influenza vaccine. We measured venous samples from Days 0, 28, and 75 for HI and VNA and B-cell ELISPOTs. Of 106 subjects, HI titers demonstrated a ceiling effect for 11 or 10% for those with a pre-vaccination HI titer of 1:640 where no subject post-vaccination had an increase in titer. Of the remaining 95 subjects, only 37 or 35% overall had at least a 4-fold increase by Day 28. Of these 37, 3 waned at least 4-fold, and 13 others 2-fold. Thus 15% of the subjects showed waning antibody titers by Day 75. More than half failed to respond at all. The profiles populated by these subjects as defined by HI did not vary with age or gender. The VNA results mimicked the HI profiles, but the profiles for B-cell ELISPOT did not. HI titers at Days 0, 28, and 75 populate 4 biologically plausible profiles. Limitations include lack of consensus for operationally defining waning as well as for the apparent ceiling. Furthermore, though well accepted as a marker for vaccine response, assigning thresholds with HI has limitations. However, VNA closely matches HI in populating these profiles. Thus, we hold that these profiles, having face- and content-validity, may provide a basis for understanding variation in genomic and transcriptomic response to influenza vaccination in this age group.
authors.affiliation: a Vaccine Research Group; Mayo Clinic ; Rochester , MN USA.
authors.forename: Robert M
authors.initials: RM
authors.lastname: Jacobson
authors.forename: Diane E
authors.initials: DE
authors.lastname: Grill
authors.forename: Ann L
authors.initials: AL
authors.lastname: Oberg
authors.forename: Pritish K
authors.initials: PK
authors.lastname: Tosh
authors.forename: Inna G
authors.initials: IG
authors.lastname: Ovsyannikova
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Poland
mesh_terms: D000368:Aged; D005260:Female; D006385:Hemagglutination Inhibition Tests / Q000379:methods*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology / Q000627:therapeutic use*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged
chemical_list: D007252:Influenza Vaccines
keywords: ASC, Antibody-Secreting Cells; ELISPOT, Enzyme-Linked ImmunoSpot; Et al., Et alia (and others); H1N1 subtype; HI, Hemagglutination-Inhibition; IQR, Interquartile Range; IgG, Immunoglobulin G; MDCK, Madin-Darby Canine Kidney; PFU, Plaque-Forming Units; RBC, Red Blood Cells; TCID50, Tissue Culture Infectious Dose 50; VNA, Virus Neutralization Assay; WHO, World Health Organization; aging; antibodies; hemagglutination inhibition tests; hemagglutinin glycoproteins; influenza a virus; influenza vaccines; influenza virus; p, p-value; viral; μl, Microliters
references.citation: J Infect Dis. 2008 Nov 1;198(9):1309-16
references.pmid: 18808338
references.citation: Curr Protoc Immunol. 2001 May;Chapter 19:Unit 19.11
references.pmid: 18432752
references.citation: Vaccine. 2009 Apr 21;27(18):2447-52
references.pmid: 19368786
references.citation: Vaccine. 2009 Aug 13;27(37):5091-5
references.pmid: 19577636
references.citation: N Engl J Med. 2009 Sep 24;361(13):1260-7
references.pmid: 19776407
references.citation: Aust J Exp Biol Med Sci. 1947 Sep;25(Pt 3):227-33
references.pmid: 20270643
references.citation: Am J Hyg. 1945 Nov;42:307-22
references.pmid: 21005133
references.citation: Nature. 2011 Feb 24;470(7335):543-7
references.pmid: 21350488
references.citation: J Infect Dis. 2011 Apr 1;203(7):921-9
references.pmid: 21357945
references.citation: J Infect Dis. 2011 May 1;203(9):1309-15
references.pmid: 21378375
references.citation: J Infect Dis. 2011 Dec 15;204(12):1879-85
references.pmid: 21998477
references.citation: PLoS Pathog. 2012 Sep;8(9):e1002920
references.pmid: 23028320
references.citation: Expert Rev Vaccines. 2013 May;12(5):519-36
references.pmid: 23659300
references.citation: Mol Syst Biol. 2013;9:659
references.pmid: 23591775
references.citation: Sci Transl Med. 2013 Mar 13;5(176):176ra32
references.pmid: 23486778
references.citation: Sci Rep. 2013;3:2327
references.pmid: 23900141
references.citation: J Infect Dis. 2013 Oct 15;208(8):1320-4
references.pmid: 23908481
references.citation: Vaccine. 2014 Feb 7;32(7):881-7
references.pmid: 24360890
references.citation: Viral Immunol. 2014 Mar;27(2):32-8
references.pmid: 24605786
references.citation: Viral Immunol. 2014 May;27(4):174-8
references.pmid: 24787023
references.citation: Immunity. 1999 Dec;11(6):733-42
references.pmid: 10626895
references.citation: J Virol. 2001 Dec;75(24):12182-7
references.pmid: 11711609
references.citation: Nat Rev Immunol. 2002 Jun;2(6):417-26
references.pmid: 12093008
references.citation: Am J Pathol. 2003 Oct;163(4):1341-55
references.pmid: 14507643
references.citation: J Immunol Methods. 2004 Mar;286(1-2):111-22
references.pmid: 15087226
references.citation: J Infect Dis. 2004 Jul 1;190(1):11-9
references.pmid: 15195238
references.citation: J Hyg (Lond). 1972 Dec;70(4):767-77
references.pmid: 4509641
references.citation: Biometrics. 1975 Mar;31(1):103-15
references.pmid: 1100130
references.citation: J Infect Dis. 1976 Jul;134(1):48-58
references.pmid: 59787
references.citation: J Clin Microbiol. 1999 Apr;37(4):937-43
references.pmid: 10074505
references.citation: Vaccine. 1999 Jan;17(1):82-94
references.pmid: 10078611
references.citation: Commun Dis Public Health. 2004 Dec;7(4):272-7
references.pmid: 15779788
references.citation: J Virol. 2006 Dec;80(23):11628-37
references.pmid: 16987975
references.citation: J Infect Dis. 2008 Feb 15;197(4):490-502
references.pmid: 18275271
references.citation: Arch Intern Med. 2008 Dec 8;168(22):2405-14
references.pmid: 19064822